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Title: Determining Risk of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on 
Epidemiologic Factors and Genetic Variants 
Abstract:  
Background & Aims: We developed comprehensive models to determine risk of Barrett’s esophagus 
(BE) or esophageal adenocarcinoma (EAC) based on genetic and non-genetic factors. 
 
Methods: We used pooled data from 3288 patients with BE, 2511 patients with EAC, and 2177 
individuals without either (controls) from participants in the international Barrett’s and EAC consortium 
as well as the United Kingdom’s BE gene study and stomach and esophageal cancer study. We collected 
data on 23 genetic variants associated with risk for BE or EAC, and constructed a polygenic risk score 
(PRS) for cases and controls by summing the risk allele counts for the variants weighted by their natural 
log-transformed effect estimates (odds ratios) extracted from genome-wide association studies. We also 
collected data on demographic and lifestyle factors (age, sex, smoking, body mass index, use of 
nonsteroidal anti-inflammatory drugs) and symptoms of gastroesophageal reflux disease (GERD). Risk 
models with various combinations of non-genetic factors and the PRS were compared for their accuracy 
in identifying patients with BE or EAC using the area under the receiver operating characteristic curve 
(AUC) analysis.  
 
Results: Individuals in the highest quartile of risk, based on genetic factors (PRS), had a 2-fold higher 
risk of BE (odds ratio [OR], 2.22; 95% CI, 1.89–2.60) or EAC (OR, 2.46; 95% CI, 2.07–2.92) than 
individual in the lowest quartile of risk based on PRS. Risk models developed based on only demographic 
or lifestyle factors or GERD symptoms identified patients with BE or EAC with AUC values ranging 
from 0.637 to 0.667. Combining data on demographic or lifestyle factors with data on GERD symptoms 
identified patients with BE with an AUC of 0.793 and patients with EAC with an AUC of 0.745. 
Including PRSs with these data only minimally increased the AUC values for BE (to 0.799) and EAC (to 
0.754). Including the PRSs in the model developed based on non-genetic factors resulted in a net 
reclassification improvement for BE of 3.0% and for EAC of 5.6%. 
 
Conclusions: We used data from 3 large databases of patients from studies of BE or EAC to develop a 
risk prediction model based on genetic, clinical, and demographic/lifestyle factors. We identified a PRS 
that increases discrimination and net reclassification of individuals with vs. without BE and EAC. 
However, the absolute magnitude of improvement is not sufficient to justify its clinical use. 
 




The incidence of esophageal adenocarcinoma (EAC) has increased sharply in many Western populations 
during the last four decades.1,2 Despite recent advances in early detection and the availability of 
endoscopic therapy for early neoplastic lesions, the estimated overall 5-year survival rate for all EAC 
patients remains poor at 18%.1,3 Most cases of EAC are diagnosed at advanced stages, with a median 
survival of less than 12 months.1  
 
Barrett’s esophagus (BE) is the precursor lesion for EAC and is a metaplastic columnar epithelium of the 
distal esophagus.4 Chronic and frequent reflux of duodenogastric contents into the distal esophagus is the 
primary risk factor for BE and EAC.5,6 The current approach to the prevention of deaths from EAC relies 
on upper endoscopy with biopsy to identify BE among individuals with frequent symptoms of 
gastroesophageal reflux disease (GERD), followed by regular endoscopic surveillance of BE to identify 
patients with neoplastic progression before invasive EAC occurs. However, only 5-7% of patients 
diagnosed with EAC have a prior diagnosis of BE,7 and a large proportion of patients with BE are 
asymptomatic and undetected,8 greatly limiting the usefulness of this strategy.  
 
An alternative approach is screening using a risk prediction model, based on demographic and clinical 
characteristics, genetic markers and other factors, for patient risk stratification. Providing clinicians with a 
tool that allows them to estimate a patient’s risk may better aid them in deciding whom to screen and 
make future resource utilization more efficient. Risk models incorporating genetic and non-genetic factors 
have been developed for predicting risks of breast cancer,9 epithelial ovarian cancer,10 and lung 
cancer,11,12 among others. Previously constructed models for EAC13,14 and BE15-19 have combined 
demographic, clinical and lifestyle information into single risk models and shown moderate 
discriminatory ability. However, no studies have examined the clinical utility of genetic-based risk 




BE and EAC are highly polygenic, with a number of overlapping genetic variants contributing to disease 
susceptibility.20,21 Taking advantage of the genetic variants identified by recent large genome-wide 
association studies (GWAS) of BE and EAC,20,22-24 we aimed to derive a polygenic risk score (PRS) and 
develop a comprehensive risk prediction model based on the PRS and a panel of well-established risk 
factors for BE or EAC (i.e., GERD symptoms, smoking status, body mass index (BMI), and use of 





The current analysis used a pooled dataset that included participants from the international Barrett’s and 
Esophageal Adenocarcinoma Consortium (BEACON; http://beacon.tlvnet.net/) GWAS, additional BE 
cases from the United Kingdom (UK) Barrett’s Esophagus Gene Study, and EAC cases from the UK 
Stomach and Oesophageal Cancer Study. The BEACON GWAS included 2,413 BE cases, 1,512 EAC 
cases and 2,185 controls of European ancestry from 14 epidemiologic studies conducted in North 
America, Western Europe, and Australia, as previously described.23 Histological confirmation of BE and 
EAC was carried out in all participating studies. Among them, after GWAS data cleaning procedures (see 
full details below), 2,406 BE cases, 1,508 EAC cases, and 2,177 controls were available for the current 
analysis. We included an additional 882 BE cases and 1,003 EAC cases from the two UK-based studies.20 
These BE cases were UK Barrett's Esophagus Gene Study participants identified at endoscopy with 
confirmed histopathological diagnoses of intestinal metaplasia.20 The EAC cases were selected from the 
UK Stomach and Oesophageal Cancer Study and had International Classification of Diseases coding of 
malignant neoplasm of the esophagus (C15) and a pathological diagnosis of adenocarcinoma (M8140-
8575).20 The final study sample included 3,288 BE cases, 2,511 EAC cases, and 2,177 controls. Each 
contributing study complied with their institutional review board requirements and all participants gave 
informed consent.  
 
Genetic variant selection, genotyping and imputation 
We selected genetic variants reported to be associated at genome-wide significance (P < 5×10-8) with risk 
of BE and/or EAC in published GWAS.20,22-24 Only the variant with the lowest P value was selected when 
multiple variants were observed in high linkage disequilibrium (LD) (r2 > 0.8). In total, 23 genetic 




Genotyping of buffy coat or whole blood DNA from all participants was performed using the Illumina 
Omni1M Quad platform, in accordance with standard quality control procedures.20,25 A detailed quality 
control of both BEACON and UK datasets has been previously described.20 In brief, all genotyped 
samples and variants met the following inclusion criteria: per variant and per sample missingness ≤ 3%; 
single nucleotide polymorphisms (SNPs) with a minor allele frequency (MAF) > 1%; SNPs with P ≥ 
0.0001 in controls and P ≥ 5 × 10-10 in BE and EAC cases for Hardy-Weinberg equilibrium, no familial 
relationships,  extreme heterozygosity rate, or outliers. Imputation was performed in each study using 
IMPUTE2 based on the 1000 Genomes Phase 1 haplotypes (June, 2014 release) reference panel.20 Post-
imputation quality control was conducted by excluding SNPs with imputation quality score < 0.4 or MAF 
< 0.01.  
 
Based on samples and variants passing standard GWAS quality control, imputed dosage data for the 23 
variants were extracted. Among them, eight variants had been directly genotyped; we therefore used the 
available genotyping data for these eight variants instead of imputation data. Imputed dosage data for the 
remaining 15 variants were converted to genotype data using GTOOL 
(http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html), and then merged with the genotypes of 
the eight directly genotyped variants. 
 
Polygenic risk score 
We constructed the PRS for cases and controls by summing the risk allele counts (i.e., participants have 0, 
1, or 2 risk alleles) for the 23 variants weighted by their natural log-transformed effect estimates (odds 
ratios) extracted from the corresponding GWAS.20,22-24 For each participant, we summed the weighted risk 
allele counts and then divided the total by 23 (i.e., the total number of loci) to derive a mean weighted 
score. The mean weighted score was then transformed into a Z score using the controls as the reference. 




Demographic, lifestyle and clinical factors 
Responses to self-reported questionnaires or interviews were collected at or near the time of BE or EAC 
diagnosis for cases and at the time of recruitment for controls. Heartburn symptoms were defined as a 
burning or aching pain behind the breastbone/sternum not attributed to heart problems, and regurgitation 
symptoms as a sour taste resulting from regurgitation of acid, bile or other stomach contents. Heartburn 
and regurgitation symptoms were harmonized and modeled dichotomously as recurrent vs. not recurrent 
based on a frequency of weekly or greater for ‘recurrent’. The term GERD will be used to refer to the 
exposure of heartburn or regurgitation symptoms or both. BMI was calculated as weight in kg divided by 
the square of height in meters (kg/m2). In this current analysis, we used usual adult weight (prior to any 
disease-related weight loss). If usual adult weight was unavailable, we used weight at 1, 5, or 20 years 
before interview, depending upon which data were available.27,28 Tobacco smoking was categorized as 
ever vs. never regular use of cigarettes. Use of NSAIDs was defined as ever vs. never regular use of any 
aspirin or non-aspirin NSAIDs. Exposures were harmonized across studies and merged into a single 
dataset for analysis. 
 
Statistical analysis 
We derived separate risk models for BE and EAC. The combined prediction model used information from 
the PRS, age, sex, GERD symptoms, smoking, BMI, and use of NSAIDs to estimate disease risk. All 
seven risk factors were entered into a logistic regression model to estimate odds ratios (OR) and 
corresponding 95% confidence intervals (95% CI). 
 
To evaluate model performance, we first used the Hosmer-Lemeshow statistic29 to assess model 
goodness-of-fit. Receiver operating characteristic curves analysis was performed and the area under the 
curve (AUC) was calculated to evaluate discriminatory performance, with repeated 10-fold cross-
validation and bootstrapping techniques used for internal validation of the risk models. To be useful, the 
predicted risks must discriminate well between those participants who do have BE/EAC (cases) and those 
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participants who do not have BE/EAC (i.e., controls). The AUC gives the probability that for any 
randomly selected pair of individuals, one case and one control, the model assigns a higher probability to 
the case. A value of 1 indicates the model has perfect discrimination, while a value of 0.5 indicates the 
model discriminates no better than chance. Likelihood ratio statistics were also computed to compare 
model fit with demographic/lifestyle factors only (age, sex, smoking, BMI, and use of NSAIDs), GERD 
symptoms only, the PRS only, and the combination of these predictors. 
 
We further assessed the clinical impact of the PRS by reclassification using the net reclassification index 
(NRI).30 The NRI, after inclusion of the PRS in the model with demographic/lifestyle factors and GERD 
symptoms, was computed as [proportion of all cases reclassified at higher risk – proportion reclassified at 
lower risk] – [proportion of all controls reclassified at higher risk – proportion reclassified at lower risk]. 
 
All data were analyzed using R software (version 3.3.3; The R Foundation for Statistical Computing, 
Vienna, Austria) and Stata version 14 (StataCorp, College Station, Texas, USA). Statistical significance 






Characteristics of the study sample are shown in Table 1. The mean ages of BE cases, EAC cases, and 
controls were 62.9, 64.5, and 61.7 years, respectively. As expected, a large proportion of cases (BE, 
75.6%; EAC, 87.3%) and controls (78.6%) were male. BE and EAC cases had higher BMI, and were 
more likely to have recurrent GERD symptoms and to have smoked compared to controls. 
 
Polygenic risk score 
The PRS was approximately normally distributed for each of the BEACON and UK datasets 
(Supplementary Figure 1). The PRS was significantly higher for case groups than in controls (P < 0.001 
for both BE vs. controls and EAC vs. controls), with mean (sd.) PRS of 0.31 (1.01) in BE, 0.36 (1.02) in 
EAC and 0.00 (1.00) in controls (Supplementary Figure 2). An increase in the PRS was associated with 
statistically significantly higher risks of BE and EAC (Table 2), adjusted for demographic/lifestyle factors 
and GERD symptoms. A risk gradient was also observed across quartiles of the PRS, such that 
individuals in the highest quartile of the PRS had over 2-fold higher risks of BE (OR, 2.22; 95% CI, 1.89-
2.60) and EAC (OR, 2.46; 95% CI, 2.07-2.92) compared to those in the lowest quartile of the PRS (Table 
2). The PRS showed poor-to-moderate predictive ability for discriminating between BE cases and 
controls (AUC, 0.588; 95% CI, 0.572-0.603) and between EAC cases and controls (AUC, 0.599; 95% CI, 
0.583-0.615) (Table 3). 
 
Combined risk prediction models 
We evaluated the predictive performance of demographic/lifestyle factors (age, sex, smoking, BMI, and 
use of NSAIDs) and GERD symptoms for discriminating BE and EAC cases from controls with and 
without the inclusion of the PRS in the models (Figure 1 & Table 3). The demographic/lifestyle-only and 
GERD symptoms-only models discriminate BE and EAC cases from controls with moderate accuracy 
(AUCs ranged from 0.637-0.667). When combined into a single model, compared with the 
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demographic/lifestyle-only and GERD symptoms-only models, the AUC values for the models with 
demographic/lifestyle factors and GERD symptoms were statistically significantly higher (BE: AUC, 
0.793; 95% CI, 0.776-0.810; EAC: AUC, 0.745; 95% CI, 0.721-0.769). 
 
With the addition of the PRS, the AUCs showed small improvement: demographic/lifestyle-only model 
increased from 0.637 to 0.656 for BE, and from 0.665 to 0.697 for EAC; and the AUC for the GERD 
symptoms-only model increased from 0.667 to 0.709 for BE, and from 0.638 to 0.684 for EAC. 
Compared with the demographic/lifestyle-GERD symptoms combined models, adding the PRS into the 
model slightly improved the prediction performance, with an AUC of 0.799 (95% CI, 0.782-0.816) for 
BE and 0.754 (95% CI, 0.729-0.778) for EAC (Figure 1, Table 3 and Supplementary Tables 2 and 3). 
Likelihood-ratio statistics were then calculated comparing the model with demographic/lifestyle-only, 
GERD symptoms-only and demographic/lifestyle-GERD symptoms combined with the models that 
included the PRS (Supplementary Table 2). While all comparisons were statistically significant (all P < 
0.001), the absolute improvement in AUCs afforded by adding the PRS was small. Upon examining the 
reclassification properties of adding the PRS to the demographic/lifestyle-GERD symptoms combined 
models for BE and EAC, we observed an overall improvement in the net risk stratification of 3.0% 
(number of participants reclassified of overall sample was 461) for BE risk prediction and 5.6% (number 
of participants reclassified of overall sample was 285) for EAC risk prediction (Table 4). 
 
Each model showed good internal validity and we found little evidence of overfitting in the repeated 10-
fold cross-validation analysis (combined model for BE: AUC, 0.797; combined model for EAC: AUC, 
0.748) (Table 3). Similar results were observed when we used bootstrapping methods for internal 
validation (combined model for BE: AUC, 0.795; combined model for EAC: AUC, 0.746). The models 
also demonstrated strong calibration in the study population (Hosmer-Lemeshow statistic, P = 0.55 for 
BE and P = 0.15 for EAC), showing good agreement between the predicted probabilities and actual 




To the best of our knowledge, this is the first study to develop a risk prediction model for BE and EAC 
combining non-genetic (demographics, lifestyle factors, and GERD symptoms) and genetic data. The 
results of this risk assessment study demonstrate that our combined risk prediction model may have 
limited clinical utility for discriminating BE and EAC cases from controls. Risk models including age, 
sex, smoking status, BMI, use of NSAIDs, and frequency of GERD symptoms showed moderate 
discriminatory ability and were well calibrated. Adding the PRS provided significantly but largely 
incremental improvements in the AUC. These data provided 3-6% improvement in the net reclassification 
index, suggesting that genetic predictors in combination with information on demographic and lifestyle 
factors and history of GERD symptoms may improve risk stratification efforts for BE and EAC, but the 
absolute magnitude of improvement may not be sufficient to justify its clinical use. 
 
Given the strong association between GERD symptoms and the risks of BE and EAC, most existing 
strategies for preventing deaths from EAC have suggested screening individuals with chronic and 
frequent GERD symptoms by endoscopy to detect BE, and monitoring those with BE by endoscopic 
biopsy surveillance to detect dysplasia or early cancers, which are amenable to endoscopic ablation and/or 
surgical resection.4,31 However, a critical limitation of these approaches, as implemented, is that most 
individuals who ultimately develop EAC (~93%) are never referred for endoscopic or other screening 
tests until they present with late-stage cancer.32 Assuming these patients had access to medical care, they 
either had asymptomatic BE (without GERD symptoms), or they had GERD symptoms not sufficiently 
severe to justify either presentation to their medical provider or endoscopy in the judgment of their 
medical provider.32 To enable more effective prevention and early detection of EAC, a key challenge lies 
in identifying the “at risk” population with greater precision. To that end, our combined prediction model 
included demographic/lifestyle (age, sex, smoking, BMI, and use of NSAIDs) factors, frequency of 
GERD symptoms and genetic factors (the PRS) to estimate relative disease risk. This is a BE/EAC-
specific model incorporating BE/EAC-specific risk factors such as GERD symptoms and the PRS. None 
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of the factors included in our combined model were used in the clinical diagnosis of BE and EAC, or used 
as part of study population recruitment for any involved study in this risk prediction model. This allows 
us to minimize overestimating the predictive ability of the integrative risk models. 
  
Previous studies have developed prediction models to estimate the absolute 5-year risk of EAC.13,14 For 
example, a study from a nation-wide population-based case-control study in Sweden used a set of readily 
available (non-genetic) factors and reported an AUC of 0.84 among 189 incident EAC cases and 820 
controls.13 An Australian study combined BMI, smoking, GERD symptoms, use of acid-suppressant 
medications and NSAIDs, and attained educational level to estimate the absolute risk of EAC from 364 
incident EAC cases and 1,580 controls, and obtained an AUC of 0.75.14 These models have not been 
validated in independent populations. Similarly, past risk prediction models for BE based on GERD 
symptoms and other non-genetic risk factors have yielded low to moderate predictive accuracy.15-19 These 
studies observed that using multiple factors improved discrimination compared with using only GERD 
symptoms (frequency and duration), but that history of GERD symptoms was a particularly important 
predictor.16,17 Consistent with these findings, GERD symptoms was the most important predictor of BE 
and EAC risk in our model, and explained the largest fraction of the phenotypic variance for BE (8.9%) 
and EAC (6.3%). However, approximately 40% of patients with EAC do not report a history of GERD 
symptoms at cancer diagnosis,33 and we showed that inclusion of additional factors in risk stratification 
(e.g., the AUC for EAC was 0.745 for the demographic/lifestyle-GERD symptoms combined model vs. 
0.638 for the GERD symptoms-only model; P < 0.001) is necessary to improve performance for clinical 
application. 
 
Recent large-scale GWAS of BE and EAC have provided an opportunity to develop risk models 
incorporating genetic variants. PRS using expanded sets of genetic variants has been reported to improve 
discrimination for diseases such as coronary heart disease, breast, lung and prostate cancer.11,34-36 
However, empirical evidence for the effectiveness of genetic risk stratification in BE and EAC is lacking. 
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In the present study, the PRS was associated with risks of BE and EAC, and accounted for 1.7% and 2.2% 
phenotypic variance of BE and EAC, respectively. Those in the highest quartile of the PRS had 122% and 
146% increased risk for BE and EAC, respectively, as compared with those with lowest quartile. How to 
best assess and quantify the improvement in a risk prediction model offered by adding new markers has 
long been a challenge. Calculating the improvement in the AUC is a traditional way to evaluate the 
prediction increment of a new marker. However, for prediction models already possessing relatively good 
discrimination, it is difficult for new promising markers to produce large increases in the AUC. For 
example, in the current study, the model including GERD symptoms and demographic/lifestyle factors 
provides reasonably good discrimination between BE/EAC cases and controls; thus, adding the PRS by 
itself does not meaningfully increase the AUC. New metrics, such as NRI, have been proposed for 
quantifying the prediction increment of a new marker,37 and have become widely used. The NRI focuses 
on reclassification tables constructed separately for cases and controls, and quantifies the correct 
movement in categories-upwards for cases and downwards for controls. In the current study, we found 
that after including the PRS in the model, 121 BE cases were reclassified as greater risk and 128 controls 
were reclassified as lower risk; while for EAC, 65 cases were corrected upwards and 100 controls 
downwards. Although the PRS assigned more individuals to the tails of the risk distributions for BE and 
EAC, the improvements were limited (3.0% and 5.6% for BE and EAC, respectively). These data 
suggested that compared with the model combining demographic/lifestyle factors and GERD symptoms, 
the additional prediction value provided by the PRS is not sufficient for clinical use. However, actively 
monitoring the individuals at the tails of this distribution may still help to identify more high risk patients 
for cancer prevention and avoid overtreatment for those individuals at lowest risk. 
 
Strengths of the current study include its large sample size of both BE and EAC cases, the high-quality 
case-control and cohort parent studies, and the available non-genetic and genetic data. The combined 
model provides moderate predictiveness for BE and EAC, with estimated AUCs of 0.799 and 0.754, 
respectively. Because internal validation indicates an upper limit of the expected performance in new 
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settings, the repeated 10-fold cross-validation and bootstrapping analysis suggested minimal overfitting of 
the models. Reclassification analysis showed small improvement of adding the PRS into the prediction 
model, suggesting potential impact of the PRS to improve the identification of individuals at higher risk 
for BE and EAC. Resequencing studies of genetic loci that are now underway might help to further refine 
the PRS of our combined models, and the identification of other, consistently associated risk factors for 
BE and EAC may also improve discrimination.  
 
Our study also has some limitations. First, only genome-wide significant GWAS variants were selected to 
generate the PRS; additional loci yet to be identified, rare variants with larger magnitudes of association 
and copy number variants should be included in future PRS. Because we selected SNPs and the 
corresponding regression coefficients for the PRS based on those SNPs identified in a meta-analysis of 
BE/EAC GWAS20 that includes a subset of participants used in the current analysis, we may have 
overestimated the predictive ability of the PRS due to overfitting. The “true” incremental improvement in 
discrimination afforded by a PRS may therefore be smaller than reported here. Although external 
validation is the gold standard because it establishes the model’s transportability and generalizability,38 
we were unable to externally validate our risk prediction models. Amassing sufficient study power for 
risk prediction analysis is a challenge, particularly given that paired clinical and GWAS data are often not 
available. Given the large worldwide consortial sample of patients participating in this work, few 
additional EA and BE patients with non-genetic and genetic data are currently available for replication, 
thus such work may require additional time for study patients to accrue. We elected to pool all studies in 
the analysis to gain the greatest statistical power and used 10-fold cross-validation and bootstrapping 
techniques for internal validation rather than a split sample approach which can lead to unstable models 
with a suboptimal predictive ability, and observed similar results.39 Although we do not have an external 
replication set, the consistency of associations of BE/EAC risk factors across BEACON studies and 
internal validation analyses suggest that our models would have adequate transportability and 
generalizability. Since we used case-control data to estimate relative risks, some level of recall bias, 
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misclassification and missing data are inevitable for exposure variables such as smoking, GERD 
symptoms, BMI, and NSAID use. Recently, central obesity (e.g., waist-to-hip ratio) has been found to be 
more strongly associated with the risks of BE and EAC than BMI; however, waist and hip measurements 
were not collected in the majority of the included studies. It is likely that adding such measures to the 
model, rather than BMI, may improve predictive ability. In addition, our model was trained in a study 
sample comprised of individuals of European ancestry; it may not be applicable to other racial or ethnic 
groups. Because our pooled dataset included some cohort studies with no controls (i.e., studies provided 
only BE or EAC cases), we were not able adjust for study site. Heterogeneity between cases and controls 
from different centers may have influenced our results and requires additional work to establish the 
transportability and generalizability of the models. Finally, our prediction models were constructed based 
on regression approaches, and used a small number of variables to predict the probability of BE or EAC. 
These traditional regression models are based on theory and assumptions and have a priori hypotheses. 
Additional advanced machine learning techniques may be able to produce a more flexible relationship 
among the predictors and the outcome and help confront issues of multiple and correlated predictors, non-
linear relationships, and interactions between predictors and endpoints, in large datasets. However, the 
output from these methods may not be as user friendly and have limited clinical utility. 
 
In conclusion, this was the first attempt to quantify the discriminatory ability of genetic factors associated 
with BE and EAC, alone and in combination with non-genetic factors. The PRS was strongly associated 
with risks of BE and EAC; however, the combined risk prediction model provided here is complex and 
the absolute difference in discriminatory ability of the combined model compared to risk models based on 
only non-genetic factors (i.e., demographic and lifestyle factors and history of GERD symptoms) was not 
sufficient to influence clinical decision-making. A better understanding and use of genetic information for 
risk prediction is needed before such integrated models could be recommended for clinical use. Future 
studies are also necessary to refine and evaluate prediction models based on data from prospective 
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Figure 1. The receiver operating characteristic curves associated with risk prediction models for A. 
Barrett’s esophagus (BE) and B. esophageal adenocarcinoma (EAC). Demographic/lifestyle model 




The following UK hospitals participated in sample collection through the Stomach and Oesophageal 
Cancer Study (SOCS) collaboration network: Addenbrooke's Hospital, University College London, 
Bedford Hospital, Hinchingbrooke Hospital, Peterborough City Hospital, West Suffolk Hospital, Norfolk 
and Norwich University Hospital, Churchill Hospital, John Radcliffe Hospital, Velindre Hospital, St 
Bartholomew's Hospital, Queen's Hospital Burton, Queen Elisabeth Hospital, Diana Princess of Wales, 
Scunthorpe General Hospital, Royal Devon & Exeter Hospital, New Cross Hospital, Belfast City 
Hospital, Good Hope Hospital, Heartlands Hospital, South Tyneside District General Hospital, 
Cumberland Infirmary, West Cumberland Hospital, Withybush General Hospital, Stoke Mandeville 
Hospital, Wycombe General Hospital, Wexham Park Hospital, Southend Hospital, Guy's Hospital, 
Southampton General Hospital, Bronglais General Hospital, Aberdeen Royal Infirmary, Manor Hospital, 
Clatterbridge Centre for Oncology, Lincoln County Hospital, Pilgrim Hospital, Grantham & District 
Hospital, St Mary's Hospital London, Croydon University Hospital, Whipps Cross University Hospital, 
Wansbeck General Hospital, Hillingdon Hospital, Milton Keynes General Hospital, Royal Gwent 
Hospital, Tameside General Hospital, Castle Hill Hospital, St Richard's Hospital, Ipswich Hospital, St 
Helens Hospital, Whiston Hospital, Countess of Chester Hospital, St Mary's Hospital IOW, Queen 
Alexandra Hospital, Glan Clwyd Hospital, Wrexham Maelor Hospital, Darent Valley Hospital, Royal 
Derby Hospital, Derbyshire Royal Infirmary, Scarborough General Hospital, Kettering General Hospital, 
Kidderminster General Hospital, Royal Lancaster Infirmary, Furness General Hospital, Westmorland 
General Hospital, James Cook University Hospital, Friarage Hospital, Stepping Hill Hospital, St George's 
Hospital London, Doncaster Royal Infirmary, Maidstone Hospital, Tunbridge Hospital, Prince Charles 
Hospital, Hartlepool Hospital, University Hospital of North Tees, Ysbyty Gwynedd, St. Jame's University 
Hospital, Leeds General Infirmary, North Hampshire Hospital, Royal Preston Hospital, Chorley and 
District General, Airedale General Hospital, Huddersfield Royal Infirmary, Calderdale Royal Hospital, 
Torbay District General Hospital, Leighton Hospital, Royal Albert Edward Infirmary, Royal Surrey 
County Hospital, Bradford Royal Infirmary, Burnley General Hospital, Royal Blackburn Hospital, Royal 
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Sussex County Hospital, Freeman Hospital, Royal Victoria Infirmary, Victoria Hospital Blackpool, 
Weston Park Hospital, Royal Hampshire County Hospital, Conquest Hospital, Royal Bournemouth 
General Hospital, Mount Vernon Hospital, Lister Hospital, William Harvey Hospital, Kent and 
Canterbury Hospital, Great Western Hospital, Dumfries and Galloway Royal Infirmary, Poole General 
Hospital, St Hellier Hospital, North Devon District Hospital, Salisbury District Hospital, Weston General 
Hospital, University Hospital Coventry, Warwick Hospital, George Eliot Hospital, Alexandra Hospital, 
Nottingham University Hospital, Royal Chesterfield Hospital, Yeovil District Hospital, Darlington 
Memorial Hospital, University Hospital of North Durham, Bishop Auckland General Hospital, Musgrove 
Park Hospital, Rochdale Infirmary, North Manchester General, Altnagelvin Area Hospital, Dorset County 
Hospital, James Paget Hospital, Derriford Hospital, Newham General Hospital, Ealing Hospital, 
Pinderfields General Hospital, Clayton Hospital, Dewsbury & District Hospital, Pontefract General 
Infirmary, Worthing Hospital, Macclesfield Hospital, University Hospital of North Staffordshire, Salford 
Royal Hospital, Royal Shrewsbury Hospital, Manchester Royal Infirmary. 
 
